Ranbaxy Laboratories is currently trading at Rs. 318.00, up by 36.10 points or 12.81% from its previous closing of Rs. 281.90 on the BSE.The scrip opened at Rs. 280.85 and has touched a high and low of Rs. 320.40 and Rs. 279.00 respectively. So far 849624 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 578.30 on 04-Sep-2012 and a 52 week low of Rs. 253.95 on 02-Aug-2013.
Last one week high and low of the scrip stood at Rs. 320.40 and Rs. 253.95 respectively. The current market cap of the company is Rs. 13451.29 crore.
The promoters holding in the company stood at 63.51% while Institutions and Non-Institutions held 20.74% and 13.69% respectively.
Ranbaxy Malaysia Sdn Bhd (RMSB) is a joint venture company of Ranbaxy Laboratories and has been allocated the site for setting up its Greenfield manufacturing facility in Malaysia. The company signed a 'letter of offer' agreement with Kulim Hi Tech Park (KHTP), a wholly owned state agency and industrial park that houses various other leading industries. KHTP is located at Kulim in the state of Kedah, Malaysia.
The Ranbaxy Greenfield facility will be built on an area of around 15 acres with an investment of around US$ 35 million providing employment to over 200 people. This will be Ranbaxy's second manufacturing plant in Malaysia. Last year in September, the Government of Malaysia gave an approval to RMSB for setting up a Greenfield manufacturing facility in Malaysia as an Entry Point Project (EPP).
The RMSB new facility would manufacture dosage forms including tablets and capsules primarily in the Cardiovascular, Anti Diabetic, Anti-infective and Gastrointestinal segments. Ranbaxy's total output in Malaysia will be increased from 1 Billion doses /annum to 3 Billion doses /annum when the new facility is fully operational. In the 2012 Malaysian budget, the Government of Malaysia liberalized investments into the healthcare sector and encouraged foreign companies.
No comments:
Post a Comment